100% Overall response rate (ORR) in triple combo study with azacitidine and venetoclax in newly diagnosed AML patients 80% CR and 90% Composite Complete Remissions (CCR); median OS not reached after 9 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback